background: menopause is associated with changes in body composition in postmenopausal women. the aim of this study was to compare the effects of tibolone and continuous combined hormone therapy (ht) on body composition in postmenopausal women. materials and methods: in this randomized clinical trial, 120 menopausal women were randomly selected and divided into three groups. of these, 40 women ...

Maintenance of neuromuscular function into old age is critical to maintain normal daily activity and functional independence. Maximal muscle strength declines with age, and the age-related loss in power might be even greater. An accelerated loss of muscle strength and power has been observed in women around the time of the menopause. The aim of the present study was to examine the effects of ti...

BACKGROUND Long-term post-menopausal hormone therapy (pHT) was often regarded as first-line therapy to prevent fractures in post-menopausal women, a recommendation under scrutiny given the benefit-risk profile of the Women's Health Initiative results of the estrogen-progestin combination. Apart from controlled clinical studies providing data with fractures as an end point, measures of lumbar an...

Tibolone is widely used in many countries (though not in the USA) for the treatment of post-menopausal symptoms and to inhibit post-menopausal bone loss. Tibolone’s popularity likely reflects the observation that it equals traditional hormone therapy in the relief of hot flushes, vaginal dryness, and the prevention of bone loss and, in addition, appears to increase libido. The post-menopausal b...

Tibolone, which is indicated for the relief of climacteric symptoms and the prevention of osteoporosis in postmenopausal women, has a tissue-specific mode of action different to that of conventional hormone replacement therapy (HRT). A large proportion of Asian postmenopausal women experience symptoms that most frequently include musculoskeletal pain, insomnia, forgetfulness, hot flushes and se...

Estrogen replacement therapy has been considered for many decades as the gold standard in the management of osteoporosis, but the risk of developing breast cancer outweighs its benefits. It is not known whether addition of another antiresorptive agent to estrogen replacement therapy will provide any beneficial effects against such risk. This in vitro study aimed to investigate the inhibitory ef...

BACKGROUND Trials demonstrate the efficacy of medications to reduce the risk for invasive breast cancer. PURPOSE To summarize benefits and harms of tamoxifen citrate, raloxifene, and tibolone to reduce the risk for primary breast cancer. DATA SOURCES MEDLINE and Cochrane databases from inception to January 2009, Web of Science, trial registries, and manufacturer information. STUDY SELECTI...

Alzheimer’s disease (AD) is a debilitating neurodegenerative characterised by the accumulation of amyloid-beta and tau in brain, leading to progressive loss memory cognition. The causes its pathogenesis are still not fully understood, but some risk factors, such as age, genetics, hormones, may play crucial role. Studies show that postmenopausal women have higher developing AD, possibly due decr...

OBJECTIVE This systematic review includes all randomized and placebo-controlled trials (RCTs) of treatment for female sexual dysfunction (FSD) in postmenopausal women published since 1990. STUDY DESIGN Electronic database and manual bibliography searches were conducted to identify all relevant publications. RESULTS Only six RCTs have been done to assess the effects of different therapies on...

1 Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543–51. 2 Schoonen WGEJ, Deckers GH, de Gooijer ME, de Ries R, Kloosterboer HJ. Hormonal properties of norethisterone, 7 -methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol 2000; 74: 213–22. 3 Kuhnz W, Heuner A, Hümpel M, Seifert W, Michaeli...